| dbo:abstract |
ميلاتوزوماب هو جسم مضاد وحيد النسيلة مرتبط بدوكسوروبيسين بدأت المرحلتين الأولى والثانية من التجارب السريرية لاستخدامه في علاج الورم النقوي المتعدد وأورام الدم الأخرى. (ar) Milatuzumab (or hLL1) is an anti-CD74 humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The drug is the first anti-CD74 antibody that has entered into human testing and is currently being studied for the treatment of multiple myeloma. Milatuzumab has received orphan drug designation from the Food and Drug Administration in the United States for the treatment of multiple myeloma and chronic lymphocytic leukemia. Milatuzumab was developed by Immunomedics, Inc, (Morris Plains NJ USA). (en) Milatuzumab è un anticorpo monoclonale umanizzato studiato per il trattamento del mieloma multiplo e di altre neoplasie ematologiche. Questo farmaco è stato sviluppato da , Inc. Il farmaco è chimicamente legato alla doxorubicina per formare un coniugato anticorpo-farmaco per il trattamento di una recidiva del mieloma multiplo. Attualmente è in corso una sperimentazione clinica di fase I/II. IL target molecolare è l'antigene: . (it) |
| dbo:casNumber |
899796-83-9 |
| dbo:fdaUniiCode |
2OP4E0GC6V |
| dbo:kegg |
D08944 |
| dbo:wikiPageExternalLink |
http://www.immunomedics.com |
| dbo:wikiPageID |
19841671 (xsd:integer) |
| dbo:wikiPageLength |
6577 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
995960139 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Antibody-drug_conjugate dbr:Orphan_drug dbr:Chronic_lymphocytic_leukemia dbr:Monoclonal_antibody dbr:Multiple_myeloma dbc:Experimental_cancer_drugs dbr:Doxorubicin dbc:Monoclonal_antibodies dbr:CD74 |
| dbp:atcPrefix |
none (en) |
| dbp:c |
6518 (xsd:integer) |
| dbp:casNumber |
899796 (xsd:integer) |
| dbp:chemspiderid |
none (en) |
| dbp:h |
10066 (xsd:integer) |
| dbp:kegg |
D08944 (en) |
| dbp:mabType |
mab (en) |
| dbp:n |
1758 (xsd:integer) |
| dbp:o |
2020 (xsd:integer) |
| dbp:s |
40 (xsd:integer) |
| dbp:source |
zu/o (en) |
| dbp:target |
dbr:CD74 |
| dbp:type |
mab (en) |
| dbp:unii |
2 (xsd:integer) |
| dbp:verifiedfields |
changed (en) |
| dbp:verifiedrevid |
458284030 (xsd:integer) |
| dbp:watchedfields |
changed (en) |
| dbp:wikiPageUsesTemplate |
dbt:As_of dbt:Cn dbt:Drugbox dbt:Refimprove_section dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Keggcite dbt:Contradicts_other dbt:Monoclonals_for_tumors |
| dct:subject |
dbc:Experimental_cancer_drugs dbc:Monoclonal_antibodies |
| gold:hypernym |
dbr:CD |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodies yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:Relation100031921 dbo:Album dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459 umbel-rc:DrugProduct |
| rdfs:comment |
ميلاتوزوماب هو جسم مضاد وحيد النسيلة مرتبط بدوكسوروبيسين بدأت المرحلتين الأولى والثانية من التجارب السريرية لاستخدامه في علاج الورم النقوي المتعدد وأورام الدم الأخرى. (ar) Milatuzumab (or hLL1) is an anti-CD74 humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The drug is the first anti-CD74 antibody that has entered into human testing and is currently being studied for the treatment of multiple myeloma. Milatuzumab has received orphan drug designation from the Food and Drug Administration in the United States for the treatment of multiple myeloma and chronic lymphocytic leukemia. Milatuzumab was developed by Immunomedics, Inc, (Morris Plains NJ USA). (en) Milatuzumab è un anticorpo monoclonale umanizzato studiato per il trattamento del mieloma multiplo e di altre neoplasie ematologiche. Questo farmaco è stato sviluppato da , Inc. Il farmaco è chimicamente legato alla doxorubicina per formare un coniugato anticorpo-farmaco per il trattamento di una recidiva del mieloma multiplo. Attualmente è in corso una sperimentazione clinica di fase I/II. IL target molecolare è l'antigene: . (it) |
| rdfs:label |
ميلاتوزوماب (ar) Milatuzumab (it) Milatuzumab (en) |
| owl:sameAs |
freebase:Milatuzumab yago-res:Milatuzumab wikidata:Milatuzumab dbpedia-ar:Milatuzumab dbpedia-fa:Milatuzumab dbpedia-it:Milatuzumab https://global.dbpedia.org/id/3aEm5 |
| prov:wasDerivedFrom |
wikipedia-en:Milatuzumab?oldid=995960139&ns=0 |
| foaf:isPrimaryTopicOf |
wikipedia-en:Milatuzumab |
| is dbo:wikiPageRedirects of |
dbr:IMMU-110 |
| is dbo:wikiPageWikiLink of |
dbr:Veltuzumab dbr:CD74 dbr:IMMU-110 dbr:Immunomedics dbr:List_of_therapeutic_monoclonal_antibodies dbr:List_of_drugs:_Meu–Mi |
| is foaf:primaryTopic of |
wikipedia-en:Milatuzumab |